Enochian Biosciences (ENOB) CFO Puche received 275,000 shares

Insider transactions reported

Luisa Puche (Chief Financial Officer at Enochian Biosciences Inc., ENOB) reported that they received 275,000 shares, and returned to the company 275,000 shares on Feb 13, 2024.

Reporting person

Puche Luisa

Role

Chief Financial Officer

Options and other derivatives

Holdings before and after

• Option to Purchase Common Stock: 60,000 to 80,000 direct

Footnotes from the filing

1. 1. The option vested in three equal installments on January 7, 2019, January 7, 2020 and January 7, 2021.
2. 2. The transactions reported herein reflect a stock option repricing (the Option Repricing ) effective on February 13, 2024 (the Repricing Date ). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the Common Stock ), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
3. 3. The option vested in three equal installments on October 26, 2021, October 26, 2022 and October 26, 2023.
4. 4. The option vested on January 22, 2023.
5. 5. One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Sale back to the company:

Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.

FAQ